Category

Acute Kidney Injury (AKI) Disease Treatment Market Size, Share, Opportunities, COVID 19 Impact, And Trends By Diagnosis (Urine Tests, Blood Tests, Glomerular Filtration Rate (GFR), Imaging Tests, Kidney Biopsy), By Treatment (Dialysis, RenalGuard Therapy, Treatment For Symptoms And Complications), And Geography - Forecasts From 2019 To 2024

Published: May 2020 | Report Code:  KSI061612284 | Pages:  96

The Acute Kidney Injury (AKI) Disease Treatment market was valued at US$29.612 billion in 2019 and is expected to grow at a CAGR of 1.09% over the forecast period to reach a market size of US$31.600 billion in 2025. The major drivers driving the growth of the global acute kidney injury (AKI) disease treatment market include the growing elderly population, the prevalence of chronic diseases, and a growing number of acute care admissions and emergency department admissions leading to ICU admission. North America and Europe are expected to hold a significant market share due to the high disease prevalence and other chronic disease prevalence which may lead to acute kidney disease while the Asia Pacific with Japan, having the maximum geriatric population in the world is expected to be the fastest-growing. In addition, rising health awareness among people, especially in developing countries will lead to frequent check-ups, emanating the market growth owing to early disease detection followed by treatment during the forecast period and beyond.
 
Major industry players profiled as part of the report are Exponential Biotherapies, Inc., NIKKISO AMERICA, INC., AM-Pharma, RenalGuard Solutions, Inc., Angion Biomedica Corp., Thrasos Therapeutics Inc., AtoxBio, and Sentien Biotechnologies, Inc.
 
Segmentation
 
The acute kidney injury (AKI) disease treatment market has been analyzed through the following segments:
 
By Diagnosis
  • Urine Tests
  • Blood Tests
  • Glomerular Filtration Rate (GFR)
  • Imaging Tests
  • Kidney Biopsy
By Type of RRT
  • Continuous
  • Intermittent
By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • Others
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Others

Frequently Asked Questions (FAQs)

Q1. What will be the acute kidney injury (AKI) disease treatment market size by 2025?
A1. The acute Kidney Injury (AKI) Disease Treatment market is expected to reach a total market size of US$31.600 billion by 2025.
 
Q2. What are the growth prospects for the acute kidney injury disease treatment market?
A2. The global acute kidney injury disease treatment market is expected to grow at a CAGR of 1.09% during the forecast period.
 
Q3. What is the size of the global acute kidney injury (AKI) disease treatment market?
A3. The acute kidney injury disease treatment market was valued at US$29.612 billion in 2019.
 
Q4. What factors are anticipated to drive acute kidney injury disease treatment market growth?
A4. The major drivers driving the growth of the global acute kidney injury (AKI) disease treatment market include the growing elderly population, the prevalence of chronic diseases, and a growing number of acute care admissions and emergency department admissions leading to ICU admission.
 
Q5. Which region holds the largest market share in the acute kidney injury disease treatment market?
A5. North America and Europe are expected to hold a significant share of the acute kidney injury (AKI) disease treatment market.

Explore custom options available with this study:

  • Request customization

  • Buy sections of the study

  • Buy country specific report

  • Request excel, Historical data

  • Subscription inquiry

  • Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.

Confidentiality

We are in compliance with the global privacy laws.

OUR CLIENTS